{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:57:50Z","timestamp":1791075470792,"version":"4.1.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In 2008, the World Health Organization introduced CEBPA (encoding the CCAAT\/enhancer binding protein)\u2013mutated acute myeloid leukemia (AML) as a provisional entity. However, the classification of CEBPA-mutated AML with multilineage dysplasia (MLD; \u2265 50% dysplastic cells in 2-3 lineages) remains to be clarified. In the present study, we investigated 108 CEBPA-mutated AML patients for the impact of MLD, karyotype, and additional mutations. MLD+ patients differed from MLD\u2212 patients only by lower mean WBC counts, not by biologic characteristics, cytogenetic risk profiles, or additional mutations. Survival was better for female patients, patients &lt; 60 years of age, for intermediate versus adverse karyotypes, and, in the case of FLT3-ITD negativity, biallelic versus monoallelic\/homozygous CEBPA mutations. In contrast, 2-year overall survival and event-free survival did not differ significantly between MLD+ and MLD\u2212 patients. By univariable Cox regression analysis, sex, age, WBC count, and cytogenetic risk category were related to overall survival, but MLD was not. Therefore, because dysplasia is not relevant for this subtype, CEBPA-mutated AML patients should be characterized only according to mutation status, cytogenetic risk group, or additional mutations.<\/jats:p>","DOI":"10.1182\/blood-2011-12-395574","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T15:50:36Z","timestamp":1332517836000},"page":"4719-4722","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity"],"prefix":"10.1182","volume":"119","author":[{"given":"Ulrike","family":"Bacher","sequence":"first","affiliation":[{"name":"Department for Stem Cell Transplantation, University of Hamburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schnittger","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Macijewski","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Grossmann","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kohlmann","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Alpermann","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kowarsch","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niroshan","family":"Nadarajah","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2019111812014775100_B1","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-09-179895","article-title":"Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.","volume":"113","author":"Wouters","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111812014775100_B2","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2019111812014775100_B3","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO.2009.26.2501","article-title":"Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.","volume":"28","author":"Green","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111812014775100_B4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2008.21.6010","article-title":"Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.","volume":"28","author":"Dufour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111812014775100_B5","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1182\/blood-2011-03-343988","article-title":"Gene mutation patterns and their prognostic impact in a cohort of 1,185 patients with acute myeloid leukemia.","volume":"118","author":"Shen","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111812014775100_B6","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1182\/blood-2008-12-194704","article-title":"The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.","volume":"113","author":"Renneville","year":"2009","journal-title":"Blood"},{"key":"2019111812014775100_B7","article-title":"The role of different genetic subtypes in CEBPA mutated AML [abstract].","volume":"116","author":"Schnittger","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"2019111812014775100_B8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2010-08-299990","article-title":"Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?","volume":"117","author":"Falini","year":"2011","journal-title":"Blood"},{"key":"2019111812014775100_B9","first-page":"110","article-title":"Acute myeloid leukemia with recurrent genetic abnormalities.","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Arber","year":"2008","edition":"4th Ed"},{"key":"2019111812014775100_B10","first-page":"124","article-title":"Acute myeloid leukaemia with myelodysplasia-related changes.","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Arber","year":"2008","edition":"4th Ed"},{"issue":"1","key":"2019111812014775100_B11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.","volume":"27","author":"B\u00fcchner","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111812014775100_B12","volume-title":"Atlas of Clinical Hematology","author":"L\u00f6ffler","year":"2004","edition":"6th Ed"},{"issue":"6","key":"2019111812014775100_B13","first-page":"520","article-title":"Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival.","volume":"6","author":"Goasguen","year":"1992","journal-title":"Leukemia"},{"issue":"4","key":"2019111812014775100_B14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111812014775100_B15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019111812014775100_B16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2019111812014775100_B17","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood-2009-08-240457","article-title":"Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).","volume":"115","author":"Falini","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/20\/4719\/1352170\/zh802012004719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/20\/4719\/1352170\/zh802012004719.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T17:06:40Z","timestamp":1574096800000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/20\/4719\/29991\/Multilineage-dysplasia-does-not-influence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":17,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2012,5,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-12-395574","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]}}}